Keyword: Vasant Narasimhan
Sandoz head Richard Francis said he can't commit to what CEO Vas Narasimhan calls "a multiyear transformation program" for the generics unit.
Pharmas often face scrutiny on price hikes for old drugs, but now investors are asking Novartis about high prices for groundbreaking new drugs.
Vas Narasimhan’s 2018 take-home pay suffered on bottom-of-the-barrel shareholder returns over three years, compared with its Big Pharma rivals.
Sweep out drug rebates for patient discounts instead? Supply chain players hate the idea, but Big Pharma CEOs are all over it.
It's been a long slog through a sluggish launch, but Novartis' highly anticipated heart drug Entresto has finally reached blockbuster status.
In the Netherlands, Lutathera's price is about five times that of some hospital-made products using the same radioactive ingredient.
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
Novartis is weighing an insurance method often associated with natural disasters to help win coverage for its next-generation cell and gene therapies.
2018 might be remembered by pharma for a deluge of consumer health castoffs. And one doesn’t really need a crystal ball to see the trend continue.
What does it take for a company to attract millennials? An inspiring culture—and jeans, according to Novartis CEO Vas Narasimhan.